Enliven Therapeutics Closes Merger with Imara and Private Placement of $165 Million
Combined company will be focused on advancing Enliven’s clinical-stage pipeline of precision oncology programs Shares to trade on Nasdaq under...
Cancer
Shattuck Labs Reports Fourth-Quarter and Full-Year 2022 Financial Results and Provides Business Updates
– Initiated enrollment in Phase 1B clinical trial of SL-172154 in combination with mirvetuximab soravtansine in platinum-resistant ovarian cancer –...
Tonix Pharmaceuticals Announces New Board Member, R. Newcomb Stillwell
CHATHAM, N.J., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage...
Relay Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Highlights
Advanced RLY-4008: Reported interim data with 88% overall response rate at pivotal dose and 63% across all doses in pan-FGFR...
Plus Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
Initiated ReSPECT-GBM Phase 2 and ReSPECT- LM Phase 1 trials for CNS cancers Awarded $17.6 million Cancer Prevention & Research...
Codexis and Nestlé Health Science Announce Interim Results from Phase 1 Clinical Trial of CDX-7108 for Exocrine Pancreatic Insufficiency
Interim Data from Phase 1 Proof-of-Concept Arm Indicates CDX-7108 Improves Lipid AbsorptionREDWOOD CITY, Calif., Feb. 23, 2023 (GLOBE NEWSWIRE) --...
International Myeloma Foundation (IMF) Launches #MYelomaSTORY Campaign for Myeloma Action Month in March 2023
STUDIO CITY, Calif., Feb. 23, 2023 (GLOBE NEWSWIRE) -- With the International Myeloma Foundation (IMF) at the forefront, Myeloma Action...
Predictive Oncology and Cvergenx announce partnership to develop the first-ever genomics-based approach to precision radiation therapy and drug discovery using artificial intelligence
EAGAN, Minn., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) and Cvergenx, Inc. today announced an agreement to...
uniQure Announces HOPE-B Clinical Trial Data Published in the New England Journal of Medicine, Demonstrating Durability and Other Benefits of HEMGENIX® (etranacogene dezaparvovec-drlb)
~ Data follow the historic approval of the first gene therapy for hemophilia B, which has been shown in clinical...
Ocean Biomedical (NASDAQ: OCEA) Celebrates Discovery of Bispecific Antibodies and Immune Checkpoint Inhibitors That Kill Glioblastoma Cells and Melanoma Cells, and Block the Metastasis of Malignant Melanoma Cells to the Lung by Over 90%
Providence, RI, Feb. 23, 2023 (GLOBE NEWSWIRE) -- As previously announced, Ocean Biomedical, Inc. (NASDAQ: OCEA) celebrates the discovery of...
Innovation Pharmaceuticals Visits BeaMed; New StingRay Laser System for Epilepsy and Brain Tumors Moving Toward FDA Submission
WAKEFIELD, MA, Feb. 23, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical...
BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3182, a CAB-EpCAMxCAB-CD3 Bispecific T-Cell Engager for the Treatment of Advanced Adenocarcinoma
Following the IND clearance, the Company is advancing into a Phase 1 clinical studyPotentially addressing most common subtypes of adenocarcinoma...
Enlivex Receives Clearance From Spanish Agency of Medicines and Medical Devices For Treatment of Patients with Advanced Solid Malignancies in the Ongoing Allocetra Phase I/II Clinical Trial
Nes-Ziona, Israel, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy...
Medigene Presents First Results for Automated Manufacturing of T Cell Receptor Engineered T Cells
MARTINSRIED, Germany and MUNICH, Germany, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Medigene AG (Medigene, FSE: MDG1, Prime Standard) is an...
Nuvectis Pharma Recaps Poster Presentation Highlights for NXP800 at the 2023 ESMO Gynecological Cancers Congress
Treatment with NXP800 resulted in substantial tumor growth inhibition in two in vivo xenograft models of ARID1a-mutated ovarian carcinoma, superior...
BriaCell Reports Positive Survival Data in Advanced Metastatic Breast Cancer
9 of 11 women remain alive from 2021/2022 dosing, highlighting strong survival benefits.Remains well tolerated with no dose limiting toxicities.Primary...
Morphic Announces Corporate Highlights and Financial Results for the Full Year 2022
-Initiated and completed enrollment for EMERALD-1 phase 2a trial of MORF-057 in ulcerative colitis; topline data expected 2Q23- -Launched EMERALD-2...
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2022 Financial Results and Highlights Recent Company Progress
Initiated the global Phase 2 study of NTLA-2002, a CRISPR-based, potential single-dose treatment for hereditary angioedema (HAE)Submitted IND application for...
BridgeBio Pharma Reports Fourth Quarter and Full Year 2022 Financial Results and Business Update
–Phase 3 ATTRibute-CM registrational trial of acoramidis for transthyretin amyloid cardiomyopathy (ATTR-CM) continues to have high operating fidelity; month 30...
Arvinas Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
– Initiated multiple trials with ARV-471, including a 2L+ Phase 3 trial for patients with metastatic breast cancer – – Presented Phase...